Carisma Therapeutics, Inc. (CARM) Price Target Analysis
Analyst Rating:
Based on 0 analystsNo Target Data
CARM trades at Wall Street's consensus target of —.
Current Price$0.02
Average Target—
Low—
Median—
High—
Analyst Target Range
Forward P/E—
PEG Ratio—
Implied Growth—
Analyst Spread—
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Consensus Scenario Assumptions
The base valuation assumes CARM achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of multiple Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
CARM Price Target Analysis
Updated June 19, 2026As of June 19, 2026, Carisma Therapeutics, Inc. (CARM) has a Wall Street consensus price target of N/A, based on estimates from 0 covering analysts. The company has a market capitalization of $795056.
Analyst price targets range from a low of N/A to a high of N/A.
The current analyst consensus rating is N/A, with 0 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. The bearish sentiment suggests caution about the stock at current levels.
From a valuation perspective, CARM trades at a trailing P/E of -0.0x.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside
+76.6%
Industry Consensus
Avg Forward P/E
34.1x
(Growth Premium)
Peers with Coverage
10 / 10
Active Analyst Tracking
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 MGTXMeiraGTx Holdings plc | $1.0B | $11.32 | $25.00 | +120.8% | Buy | — | 6 |
 FATEFate Therapeutics, Inc. | $244M | $2.09 | $5.50 | +163.2% | Buy | — | 31 |
 SANASana Biotechnology, Inc. | $877M | $3.15 | $8.67 | +175.2% | Buy | — | 11 |
 BEAMBeam Therapeutics Inc. | $3.5B | $34.14 | $48.00 | +40.6% | Buy | — | 27 |
 NTLAIntellia Therapeutics, Inc. | $1.8B | $15.67 | $26.13 | +66.8% | Buy | — | 39 |
 CRSPCRISPR Therapeutics AG | $5.2B | $54.09 | $71.67 | +32.5% | Buy | — | 38 |
 KYMRKymera Therapeutics, Inc. | $7.4B | $90.43 | $112.60 | +24.5% | Buy | — | 26 |
 ALNYAlnylam Pharmaceuticals, Inc. | $37.1B | $278.09 | $454.27 | +63.4% | Buy | 37.1x | 52 |
 EDITEditas Medicine, Inc. | $263M | $2.69 | $5.00 | +85.9% | Buy | — | 25 |
 ILMNIllumina, Inc. | $24.6B | $161.93 | $151.40 | -6.5% | Buy | 31.0x | 50 |
CARM — Frequently Asked Questions
Quick answers to the most common questions about buying CARM stock.
What is the CARM stock price target for 2026?
The consensus price target for CARM is $N/A, close to the current price of $0.019 (N/A% implied move). Based on 0 analyst estimates, the stock appears fairly valued near current levels.
Is CARM a buy, sell, or hold?
CARM has a consensus rating of "N/A" based on 0 Wall Street analysts. The rating breakdown is mixed, with 0 Hold ratings making up the largest segment. The consensus 12-month price target of $N/A implies N/A% upside from current levels.
Is CARM stock overvalued or undervalued?
CARM's current price is $0.019 with a consensus target of $N/A (N/A% implied move). Analyst estimates suggest the stock is fairly valued at current levels.
How high can CARM stock go?
The most bullish Wall Street analyst has a price target of $N/A for CARM, while the most conservative target is $N/A. The consensus of $N/A represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover CARM stock?
CARM is lightly followed, with 0 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 0 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the CARM stock forecast?
The 12-month CARM stock forecast based on 0 Wall Street analysts shows a consensus price target of $N/A, with estimates ranging from $N/A (bear case) to $N/A (bull case). The median consensus rating is "N/A".
Should I buy CARM stock?
CARM appears fairly valued according to analysts, with a "N/A" rating and minimal upside to the $N/A target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do CARM price targets vary so much?
CARM analyst price targets range from $N/A to $N/A, a NaN% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $N/A consensus represents the middle ground.
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare